Physician profile
Kelly Shaffer
NPI 1962681577
$4,704.72
in general payments reported to CMS, 2019-2025
28 companies · $1,865 in 2025
The $1,865 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.46 · 2023: $999 · 2024: $1,810 · 2025: $1,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,674.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,481.00 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $899.50 | 2021-2025 | |
| Lilly USA, LLC | $407.38 | 2023-2025 | Emgality, Jardiance, Reyvow |
| Astrazeneca Pharmaceuticals LP | $379.30 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $307.41 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $284.81 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Teva Pharmaceuticals USA, INC. | $255.84 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Phathom Pharmaceuticals, INC. | $128.14 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $64.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $55.02 | 2023-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $45.70 | 2024-2025 | |
| Neurelis, INC. | $39.38 | 2023 | Valtoco |
| Astellas Pharma US INC | $38.43 | 2023-2024 | Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $38.39 | 2024-2025 | Hyqvia |
| Eisai INC. | $33.00 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $28.58 | 2025 | Nuplazid |
| Axsome Therapeutics, INC. | $27.05 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $22.01 | 2025 | Fanapt, Hetlioz |
| Ucb, INC. | $20.55 | 2025 | Nayzilam |
| Azurity Pharmaceuticals, INC. | $18.94 | 2024 | Horizant |
| Lundbeck LLC | $17.53 | 2025 | Vyepti |
| Insulet Corporation | $17.36 | 2025 | Omnipod |
| Inspire Medical Systems, INC. | $17.02 | 2024 | Inspire |
| Amgen INC. | $16.53 | 2025 | Repatha, Otezla |
| Biogen, INC. | $16.17 | 2025 | Leqembi |
| Aprecia Pharmaceuticals, LLC | $16.14 | 2023 | Spritam |
| Otsuka America Pharmaceutical, INC. | $15.04 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.15 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.